Should ketamine be used for the clinical treatment of depression?

Abstract

Objective:

There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression.

Conclusions:

Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine’s adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.

Keywords

ketamine depression pharmacotherapy

Get full access to this article

View all access options for this article.

References

World Health Organization. Fact Sheet Number 369: Depression. 2012; http://www.who.int/mediacentre/factsheets/fs369/en/.

Fava

Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649–659.

Berman

Cappiello

Anand

. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354.

Domino

EF.

Taming the ketamine tiger. 1965. Anesthesiology 2010; 113: 678–684.

Advisory Council on the Misuse of Drugs. Ketamine: A review of use and harm. 2013.

Sanacora

Schatzberg

AF.

Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders?

Neuropsychopharmacology 2015; 40: 259–267.

McGirr

Berlim

Bond

. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45: 693–704.

Katalinic

Lai

Somogyi

. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Aust N Z J Psychiatry 2013; 47: 710–727.

Lee

Della Selva

Liu

. Ketamine as a novel treatment for major depressive disorder and bipolar depression: A systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015; 37: 178–184.

10.

Murrough

Perez

Pillemer

. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250–256.

11.

Rasmussen

KG.

Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Prog Neuropsychopharmacol Biol Psychiatry 2016; 64: 218-224.

12.

Murrough

Iosifescu

Chang

. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.

13.

aan het Rot

Collins

Murrough

. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67: 139–145.

14.

Barnes

How prescription drugs are developed. Australian Prescriber 2006; 29: 159.

15.

Diamond

Farmery

Atkinson

. Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014; 28: 536-544.

16.

Wolff

Winstock

AR.

Ketamine. CNS Drugs 2006; 20: 199–218.

17.

Tse

. Emergency department presentation of ketamine abusers in Hong Kong: A review of 233 cases. Hong Kong Med J 2010; 16: 6–11.

18.

Yiu-Cheung

Acute and chronic toxicity pattern in ketamine abusers in Hong Kong. J Med Toxicol 2012; 8: 267–270.

19.

Kirby

Ketamine for depression: the highs and lows. Lancet Psychiatry 2015; 2: 783–784.